

Anti-PD-1 (Pembrolizumab), Humanized Antibody

CATALOG NO:	A1306-100
ALTERNATE NAMES:	Programmed Cell Death 1; CD279; SLEB2; HPD-L; PDCD1
AMOUNT:	100 µg
IMMUNOGEN:	Human programmed cell death 1 receptor (PD-1)
HOST/ISOTYPE:	Human IgG4
CLONALITY:	Monoclonal
SOURCE:	CHO cells
ENDOTOXIN LEVELS:	≤ 1 EU/mg
CAS NO.:	1374853-91-4
SPECIES REACTIVITY:	Human
FORM:	Liquid
FORMULATION:	Supplied in phosphate buffered saline, pH 7.2
STORAGE CONDITIONS:	Store the undiluted solution at 4 °C in the dark. Avoid repeated freeze-thaw cycles
SPECIFICITY:	This research-grade biosimilar is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
DESCRIPTION:	PD-1 has a critical function in the prevention of autoimmunity. This research-grade biosimilar binds to the human immune cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the re-activation of T-cell-mediated immune responses against tumor cells. The original humanized monoclonal antibody has been approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma.

Note: This information is only intended as a guide. The optimal dilutions must be determined by the user.

RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), Humanized Antibody (**Cat. No. A1045-100**)
- Anti-EGFR (Cetuximab), Chimeric Antibody (**Cat. No. A1047-100**)
- Anti-HER2 (Trastuzumab), Humanized Antibody (**Cat. No. A1046-100**)
- Anti-CD20 (Rituximab), Chimeric Antibody (**Cat. No. A1049-100**)
- Anti-EGFR (Panitumumab), Humanized Antibody (**Cat. No. A1050-100**)
- Anti-PD-L1, Humanized Antibody (**Cat. No. A1305-100**)
- Anti-PD-1 (Nivolumab), Humanized Antibody (**Cat. No. A1307-100**)

FOR RESEARCH USE ONLY! Not to be used on humans.